Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.

Bernasconi E, Gaudio E, Lejeune P, Tarantelli C, Cascione L, Kwee I, Spriano F, Rinaldi A, Mensah AA, Chung E, Stathis A, Siegel S, Schmees N, Ocker M, Zucca E, Haendler B, Bertoni F.

Br J Haematol. 2017 Sep;178(6):936-948. doi: 10.1111/bjh.14803. Epub 2017 Jun 27.

PMID:
28653353
2.

Biliary tract cancer stem cells - translational options and challenges.

Mayr C, Ocker M, Ritter M, Pichler M, Neureiter D, Kiesslich T.

World J Gastroenterol. 2017 Apr 14;23(14):2470-2482. doi: 10.3748/wjg.v23.i14.2470. Review.

3.

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.

Bahleda R, Grilley-Olson JE, Govindan R, Barlesi F, Greillier L, Perol M, Ray-Coquard I, Strumberg D, Schultheis B, Dy GK, Zalcman G, Weiss GJ, Walter AO, Kornacker M, Rajagopalan P, Henderson D, Nogai H, Ocker M, Soria JC.

Br J Cancer. 2017 Jun 6;116(12):1505-1512. doi: 10.1038/bjc.2017.92. Epub 2017 May 2.

PMID:
28463960
4.

Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer.

Jäger T, Ocker M, Kiesslich T, Neureiter E, Neureiter D.

Expert Opin Investig Drugs. 2017 Feb;26(2):133-136. doi: 10.1080/13543784.2017.1274392. Epub 2016 Dec 27. No abstract available.

PMID:
28004600
5.

Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.

Tanwar S, Trembling PM, Hogan BJ, Srivastava A, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM.

Eur J Gastroenterol Hepatol. 2017 Mar;29(3):289-296. doi: 10.1097/MEG.0000000000000789.

PMID:
27906753
6.

Fibromyalgia syndrome: metabolic and autophagic processes in intermittent cold stress mice.

Oezel L, Then H, Jung AL, Jabari S, Bonaterra GA, Wissniowski TT, Önel SF, Ocker M, Thieme K, Kinscherf R, Di Fazio P.

Pharmacol Res Perspect. 2016 Sep 27;4(5):e00248. eCollection 2016 Oct. Erratum in: Pharmacol Res Perspect. 2016 Nov 24;4(6):e00277.

7.

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.

Kim SM, Kim H, Yun MR, Kang HN, Pyo KH, Park HJ, Lee JM, Choi HM, Ellinghaus P, Ocker M, Paik S, Kim HR, Cho BC.

Oncogenesis. 2016 Jul 18;5(7):e241. doi: 10.1038/oncsis.2016.48.

8.

Biomarkers of Hepatic Fibrosis in Chronic Hepatitis C: A Comparison of 10 Biomarkers Using 2 Different Assays for Hyaluronic Acid.

Tanwar S, Trembling PM, Hogan BJ, Parkes J, Harris S, Grant P, Nastouli E, Ocker M, Wehr K, Herold C, Neureiter D, Schuppan D, Rosenberg WM.

J Clin Gastroenterol. 2017 Mar;51(3):268-277. doi: 10.1097/MCG.0000000000000581.

PMID:
27380461
9.

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer.

Di Fazio P, Waldegger P, Jabari S, Lingelbach S, Montalbano R, Ocker M, Slater EP, Bartsch DK, Illig R, Neureiter D, Wissniowski TT.

Oncotarget. 2016 May 17;7(20):28998-9010. doi: 10.18632/oncotarget.8585.

10.

Morphological Alterations in Gastrocnemius and Soleus Muscles in Male and Female Mice in a Fibromyalgia Model.

Bonaterra GA, Then H, Oezel L, Schwarzbach H, Ocker M, Thieme K, Di Fazio P, Kinscherf R.

PLoS One. 2016 Mar 17;11(3):e0151116. doi: 10.1371/journal.pone.0151116. eCollection 2016.

11.

Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells.

Montalbano R, Honrath B, Wissniowski TT, Elxnat M, Roth S, Ocker M, Quint K, Churin Y, Roederfeld M, Schroeder D, Glebe D, Roeb E, Di Fazio P.

Oncotarget. 2016 Apr 12;7(15):20312-23. doi: 10.18632/oncotarget.7950.

12.

Erratum to: DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions.

Gandesiri M, Chakilam S, Ivanovska J, Benderska N, Ocker M, Di Fazio P, Feoktistova M, Gali-Muhtasib H, Rave-Fränk M, Prante O, Christiansen H, Leverkus M, Hartmann A, Schneider-Stock R.

Apoptosis. 2016 May;21(5):671-4. doi: 10.1007/s10495-016-1224-7. No abstract available.

PMID:
26960313
13.

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.

Gelato KA, Shaikhibrahim Z, Ocker M, Haendler B.

Expert Opin Ther Targets. 2016 Jul;20(7):783-99. doi: 10.1517/14728222.2016.1134490. Epub 2016 Jan 22. Review.

PMID:
26799480
14.

In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.

Maschauer S, Gahr S, Gandesiri M, Tripal P, Schneider-Stock R, Kuwert T, Ocker M, Prante O.

Nucl Med Biol. 2016 Jan;43(1):27-34. doi: 10.1016/j.nucmedbio.2015.10.003. Epub 2015 Oct 20.

PMID:
26702784
15.

The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.

Mayr C, Wagner A, Loeffelberger M, Bruckner D, Jakab M, Berr F, Di Fazio P, Ocker M, Neureiter D, Pichler M, Kiesslich T.

Oncotarget. 2016 Jan 5;7(1):745-58. doi: 10.18632/oncotarget.6378.

16.

Jet printing of convex and concave polymer micro-lenses.

Blattmann M, Ocker M, Zappe H, Seifert A.

Opt Express. 2015 Sep 21;23(19):24525-36. doi: 10.1364/OE.23.024525.

PMID:
26406656
17.

3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.

Mayr C, Wagner A, Stoecklinger A, Jakab M, Illig R, Berr F, Pichler M, Di Fazio P, Ocker M, Neureiter D, Kiesslich T.

Anticancer Res. 2015 Sep;35(9):4697-705.

PMID:
26254359
18.

The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression.

Gahr S, Mayr C, Kiesslich T, Illig R, Neureiter D, Alinger B, Ganslmayer M, Wissniowski T, Fazio PD, Montalbano R, Ficker JH, Ocker M, Quint K.

Int J Oncol. 2015 Sep;47(3):963-70. doi: 10.3892/ijo.2015.3087. Epub 2015 Jul 16.

PMID:
26202945
19.

Roscovitine has anti-proliferative and pro-apoptotic effects on glioblastoma cell lines: A pilot study.

Kolodziej M, Goetz C, Di Fazio P, Montalbano R, Ocker M, Strik H, Quint K.

Oncol Rep. 2015 Sep;34(3):1549-56. doi: 10.3892/or.2015.4105. Epub 2015 Jul 3.

PMID:
26151768
20.

Correction: pathological impact of hepatitis B virus surface proteins on the liver is associated with the host genetic background.

Churin Y, Roderfeld M, Stiefel J, Würger T, Schröder D, Matono T, Mollenkopf HJ, Montalbano R, Pompaiah M, Reifenberg K, Zahner D, Ocker M, Gerlich W, Glebe D, Roeb E.

PLoS One. 2015 May 1;10(5):e0127375. doi: 10.1371/journal.pone.0127375. eCollection 2015. No abstract available.

Supplemental Content

Support Center